Genentech's Tecentriq Misses Key Endpoint in Advanced-Stage Ovarian Cancer
13 July 2020 - 8:27PM
Dow Jones News
By Colin Kellaher
Roche Holding AG's Genentech unit on Monday said a phase 3 study
of Tecentriq in advanced-stage ovarian cancer missed a main
endpoint.
Genentech said the addition of Tecentriq to Avastin, paclitaxel
and carboplatin didn't meet its primary endpoint of
progression-free survival for the front-line treatment of women
with newly diagnosed advanced-stage ovarian cancer.
Genentech said it is disappointed by the study results, adding
that ovarian cancer is one of the most aggressive cancers and is
difficult to treat in its advanced stages.
The company said data for the overall survival co-primary
endpoint are currently immature, and that follow-up will continue
until the next planned analysis.
Genentech noted that it has an extensive development program for
Tecentriq, including multiple ongoing and planned phase III studies
across several cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 13, 2020 06:12 ET (10:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024